Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials.

Papi A, Wise RA, Jackson DJ, Lugogo N, Chen R, Trasieva T, Obasi C, Movitz C, Helman J, Salter P, Springer K, Bondoc M, Shah M, Knappenberger K, Bowen K, Pandya H, Megally A, Patel M, KALOS and LOGOS study investigators

Open source

DOI: 10.1016/s2213-2600(25)00457-6
Published: 2026 Apr
Container: The Lancet. Respiratory medicine
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2213-2600-25-00457-6,
  title = {Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials.},
  author = {Papi A and Wise RA and Jackson DJ and Lugogo N and Chen R and Trasieva T and Obasi C and Movitz C and Helman J and Salter P and Springer K and Bondoc M and Shah M and Knappenberger K and Bowen K and Pandya H and Megally A and Patel M and KALOS and LOGOS study investigators},
  year = {2026},
  journal = {The Lancet. Respiratory medicine},
  doi = {10.1016/s2213-2600(25)00457-6},
  url = {https://doi.org/10.1016/s2213-2600(25)00457-6}
}

RIS

TY  - JOUR
TI  - Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials.
AU  - Papi A
AU  - Wise RA
AU  - Jackson DJ
AU  - Lugogo N
AU  - Chen R
AU  - Trasieva T
AU  - Obasi C
AU  - Movitz C
AU  - Helman J
AU  - Salter P
AU  - Springer K
AU  - Bondoc M
AU  - Shah M
AU  - Knappenberger K
AU  - Bowen K
AU  - Pandya H
AU  - Megally A
AU  - Patel M
AU  - KALOS and LOGOS study investigators
PY  - 2026
JO  - The Lancet. Respiratory medicine
DO  - 10.1016/s2213-2600(25)00457-6
UR  - https://doi.org/10.1016/s2213-2600(25)00457-6
ER  -

APA

A, P., RA, W., DJ, J., N, L., R, C., T, T., C, O., C, M., J, H., P, S., K, S., M, B., M, S., K, K., K, B., H, P., A, M., M, P., & investigators, K. A. L. S. (2026). Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials.. The Lancet. Respiratory medicine. https://doi.org/10.1016/s2213-2600(25)00457-6

Source records

pubmed · retrieved 2026-09-26T17:18:34.744Z